Regulation of SIV antigen-specific CD4+ T cellular immunity via autophagosome-mediated MHC II molecule-targeting antigen presentation in mice

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Jin, Yi ^a,b   Sun, Caijun ^a   Feng, Liqiang ^a   Li, Pingchao ^a   Xiao, Lijun ^a,b   Ren, Yizhong ^a,c   Wang, Dimin ^a,d   Li, Chufang ^e   Chen, Ling ^a,e  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d ANHUI UNIVERSITY   (China)

^e GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROTUBULE ASSOCIATED PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 1 LIGHT CHAIN 3 BETA; UNCLASSIFIED DRUG; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOMODULATION; LYSOSOME; MOUSE; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; HELA CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PHAGOSOME; PHYSIOLOGY; PROTEIN TRANSPORT; SECRETION (PROCESS); VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; AUTOPHAGY; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENE PRODUCTS, GAG; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MICE, INBRED C57BL; MICROTUBULE-ASSOCIATED PROTEINS; PHAGOSOMES; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84899786639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093143     Document Type: Article

References (53)

1. Heeney JL, Plotkin SA (2006) Immunological correlates of protection from HIV infection and disease. Nat Immunol 7: 1281-1284. (Pubitemid 46111246)
2. Moog C (2008) Immune responses that correlate with HIV-1 protection? AIDS 22: 1461-1462.
3. Esparza J (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31: 3502-3518.
4. Walker CM, Moody DJ, Stites DP, Levy JA (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563-1566. (Pubitemid 17125280)
5. Sun C, Chen Z, Tang X, Zhang Y, Feng L, et al. (2013) Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. J Virol 87: 5669-5677.
6. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
7. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, et al. (2012) Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491: 129-133.
8. McDermott AB, Koup RA (2012) CD8(+) T cells in preventing HIV infection and disease. AIDS 26: 1281-1292.
9. Cohen J (2007) AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 318: 28-29.
10. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
11. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, et al. (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-ofconcept phase 2b study. Lancet Infect Dis 11: 507-515.
12. McEnery R (2011) HVTN 505 trial expanded to see if vaccine candidates can block HIV acquisition. IAVI Rep 15: 17.
13. Cohen J (2013) AIDS research. More woes for struggling HIV vaccine field. Science 340: 667.
14. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, et al. (2012) HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 4: 123ra125.
15. Streeck H, D'Souza MP, Littman DR, Crotty S (2013) Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med 19: 143-149.
16. Gauduin MC, Yu Y, Barabasz A, Carville A, Piatak M, et al. (2006) Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med 203: 2661-2672. (Pubitemid 44833342)
17. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450. (Pubitemid 27509814)
18. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, et al. (2011) HIV-1- specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 85: 733-741.
19. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176.
20. Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5: 386-390.
21. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
23. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, et al. (2011) Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 203: 969-975.
24. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
25. Kadowaki M, Karim MR, Carpi A, Miotto G (2006) Nutrient control of macroautophagy in mammalian cells. Mol Aspects Med 27: 426-443. (Pubitemid 44479873)
26. Mehrpour M, Esclatine A, Beau I, Codogno P (2010) Overview of macroautophagy regulation in mammalian cells. Cell Res 20: 748-762.
27. Deretic V, Levine B (2009) Autophagy, immunity, and microbial adaptations. Cell Host Microbe 5: 527-549.
28. Campbell GR, Spector SA (2013) Inhibition of human immunodeficiency virus type-1 through autophagy. Curr Opin Microbiol 16: 349-354.
29. Richetta C, Faure M (2013) Autophagy in antiviral innate immunity. Cell Microbiol 15: 368-376.
30. Valdor R, Macian F (2012) Autophagy and the regulation of the immune response. Pharmacol Res 66: 475-483.
31. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ (2012) Autophagy and the immune system. Annu Rev Immunol 30: 611-646.
32. Oh JE, Lee HK (2012) Autophagy in innate recognition of pathogens and adaptive immunity. Yonsei Med J 53: 241-247.
33. Ireland JM, Unanue ER (2011) Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 208: 2625-2632.
34. Heath WR, Carbone FR (2001) Cross-presentation in viral immunity and selftolerance. Nat Rev Immunol 1: 126-134.
35. Schmid D, Pypaert M, Munz C (2007) Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 26: 79-92. (Pubitemid 46109341)
36. English L, Chemali M, Duron J, Rondeau C, Laplante A, et al. (2009) Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 10: 480-487.
37. Li Y, Wang LX, Yang G, Hao F, Urba WJ, et al. (2008) Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 68: 6889-6895.
38. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307: 593-596. (Pubitemid 40165684)
39. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, et al. (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33: 1250-1259. (Pubitemid 36609143)
40. Gannage M, da Silva RB, Munz C (2013) Antigen processing for MHC presentation via macroautophagy. Methods Mol Biol 960: 473-488.
41. Tey SK, Khanna R (2012) Host immune system strikes back: autophagy-mediated antigen presentation bypasses viral blockade of the classic MHC class I processing pathway. Autophagy 8: 1839-1841.
42. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, et al. (2003) Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 7663-7668. (Pubitemid 36734536)
43. Sun Y, Liu G, Li Z, Chen Y, Liu Y, et al. (2013) Modulation of dendritic cell function and immune response by cysteine protease inhibitor from murine nematode parasite Heligmosomoides polygyrus. Immunology 138: 370-381.
44. Sun C, Zhang L, Zhang M, Liu Y, Zhong M, et al. (2010) Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys. J Infect 60: 371-381.
45. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, et al. (2005) Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 102: 7922-7927. (Pubitemid 40781039)
46. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, et al. (2001) In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol 31: 1485-1494. (Pubitemid 32454696)
47. Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595-602.
48. Kumamoto Y, Mattei LM, Sellers S, Payne GW, Iwasaki A (2011) CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A 108: 8749-8754.
49. Soghoian DZ, Streeck H (2010) Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 9: 1453-1463.
50. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097. (Pubitemid 40663481)
51. Sun Y, Permar SR, Buzby AP, Letvin NL (2007) Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol 81: 8009-8015. (Pubitemid 47101486)
52. Porichis F, Kaufmann DE (2011) HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 6: 174-180.
53. Sun Y, Schmitz JE, Buzby AP, Barker BR, Rao SS, et al. (2006) Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 80: 10950-10956. (Pubitemid 44706536)